UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" of exosomes—tiny particles released from cancer cells in the ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ...

Liquid biopsy, or the evaluation of malignancies using biomarkers found in bodily fluids, has gained popularity in recent years. Technologies that can detect and describe cancers in minimally ...

Post this The European liquid biopsy market, valued at $1.24 billion in 2024, is expected to reach $5.58 billion by 2033, exhibiting a robust CAGR of 18.18% during the forecast period 2024-2033.

The liquid biopsy market is experiencing significant changes, and The Worldwide Market for Liquid Biopsy, 6th Edition provides an in-depth assessment of the market opportunity from 2023 to 2028.